Free provider profile
SATISH NARAYAN, MD
NPI 1194787200
Individual
Psychiatry & Neurology, Psychiatry
Active registration
Save to rep workspaceNPI registry Registry record
Source: CMS NPPES registry, updated continuously. This record was last updated 2022-11-22.
7170 PRESTON RD STE 200, PLANO, TX, 75024
972-232-7474
4 practice locations listed
Enumerated 2006-04-04
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 4 practice locations listed — multi-site footprint.
- — 3 taxonomies listed — broader service mix.
- — 3 payer identifiers on file — enrolled with payers.
- — Record last updated 3 years ago.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
4,433
Medicare patients
330
Part D drug cost
$1,352,991
Brand-name share
14.3%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Austedo Xr (Deutetrabenazine) | 43 | $422,480 |
| Spravato (Esketamine Hcl) | 231 | $286,394 |
| Austedo (Deutetrabenazine) | 26 | $243,213 |
| Auvelity (Dextromethorphan Hbr/Bupropion) | 70 | $77,774 |
| Invega Sustenna (Paliperidone Palmitate) | 17 | $51,516 |
| Rexulti (Brexpiprazole) | 14 | $46,076 |
| Belsomra (Suvorexant) | 61 | $26,271 |
| Caplyta (Lumateperone Tosylate) | 14 | $23,234 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Spravato (esketamine) Medicare billing
Source: CMS Medicare Part B fee-for-service, HCPCS G2082/G2083.
2024210 sessions · 11 patients · $195,167
Full Spravato label-compliance detail — sessions per patient against the FDA label, risk flags and year-over-year trend.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.